{"id":"NCT00689936","sponsor":"Celgene","briefTitle":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","officialTitle":"A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-21","primaryCompletion":"2016-07-14","completion":"2016-07-14","firstPosted":"2008-06-04","resultsPosted":"2017-08-11","lastUpdate":"2019-11-20"},"enrollment":1623,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Lenalidomide and low-dose dexamethasone","otherNames":["Revlimid"]},{"type":"DRUG","name":"Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles","otherNames":["Revlimid"]},{"type":"DRUG","name":"Melphalan, Prednisone and Thalidomide","otherNames":["Prednisone","Thalomid"]}],"arms":[{"label":"Lenalidomide / Dexamethasone until disease progression","type":"EXPERIMENTAL"},{"label":"Lenalidomide / Dexamethasone for 18 cycles","type":"EXPERIMENTAL"},{"label":"Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.","primaryOutcome":{"measure":"Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)","timeFrame":"From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.","effectByArm":[{"arm":"Lenalidomide and Low-Dose Dexamethasone (Rd)","deltaMin":25.5,"sd":null},{"arm":"Lenalidomide and Dexamethasone Rd18","deltaMin":20.7,"sd":null},{"arm":"Melphalan + Prednisone + Thalidomide (MPT)","deltaMin":21.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.00006"},{"comp":"OG000 vs OG001","p":"0.00001"},{"comp":"OG001 vs OG002","p":"0.70349"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":288,"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Greece","Ireland","Italy","New Zealand","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["26659916","27325857","25769541","25184863","28641472","29784907","29980678","30244101","29150421","30773308","30859608","28373701","28106903"],"seeAlso":["http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses"]},"adverseEventsSummary":{"seriousAny":{"events":378,"n":532},"commonTop":["CONSTIPATION","NEUTROPENIA","ANAEMIA","OEDEMA PERIPHERAL","DIARRHOEA"]}}